While recent research has shown that the accuracy of positive identification decisions can be assessed via confidence and decision times, gauging lineup rejections has been less successful. The current study focused on 2 different aspects which are inherent in lineup rejections. First, we hypothesized that decision times and confidence ratings should be postdictive of identification rejections if they refer to a single lineup member only. Second, we hypothesized that dividing nonchoosers according to the reasons they provided for their decisions can serve as a useful postdictor for nonchoosers' accuracy. To test these assumptions, we used (1) 1-person lineups (showups) in order to obtain confidence and response time measures referring to a single lineup member, and (2) asked nonchoosers about their reasons for making a rejection. Three hundred and eighty-four participants were asked to identify 2 different persons after watching 1 of 2 stimulus films. The results supported our hypotheses. Nonchoosers' postdecision confidence ratings were well-calibrated. Likewise, we successfully established optimum time and confidence boundaries for nonchoosers. Finally, combinations of postdictors increased the number of accurate classifications compared with individual postdictors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037/h0093926 | DOI Listing |
CJEM
January 2025
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada.
Objectives: Fundoscopy is crucial in the emergency department to identify or rule out serious ocular and neurological conditions. Despite its clinical importance, fundoscopy is often omitted due to the technical challenges associated with traditional direct ophthalmoscopy, particularly for non-ophthalmologists. This study examines emergency physicians' practices, confidence levels, and training related to various modalities of fundoscopy including traditional direct ophthalmoscopes, binocular indirect ophthalmoscopes, panoptic ophthalmoscopes, slit lamp fundoscopy and fundus cameras; and explores the potential role of alternative modalities, such as fundus cameras, in Canadian emergency departments.
View Article and Find Full Text PDFRadiat Oncol
January 2025
Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
Introduction: Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary lesion and lymph node metastases, combined with local consolidative therapy (LCT) for oligometastases.
Methods: This was a multicenter Phase II trial for patients with Stage IV NSCLC with oligometastases for whom CRT for thoracic disease was feasible.
Am J Clin Nutr
January 2025
Laboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, United States. Electronic address:
Background: Continuous glucose monitors (CGMs) are used to characterize postprandial glucose responses and provide personalized dietary advice to minimize glucose excursions. The efficacy of such advice depends on reliable glucose responses.
Objectives: To explore within-subject variability of CGM responses to duplicate presented meals in an inpatient setting.
Respir Med
January 2025
Division of Pulmonology, Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, Gyeonggi-do, Republic of Korea. Electronic address:
Introduction: Ca2+ signaling in fibroblasts would be one of the important mediators of lung fibrosis. This study investigated the relationship between calcium channel blocker usage and the risk of developing interstitial lung disease and idiopathic pulmonary fibrosis.
Material And Methods: This cohort study used data from the Korean National Health Screening Cohort spanned from January 1, 2004, to December 31, 2015.
J Thorac Oncol
January 2025
Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa-Nishi-machi, Kanagawa-ku, Yokohama 221-0855, Japan.
Introduction: Osimertinib is the first-line treatment for patients with non-small cell lung cancer (NSCLC) who have EGFR mutations and favorable performance status (PS). Despite increasing clinical data on osimertinib, evidence in patients with an impaired PS remains limited. Therefore, a multicenter phase II trial (OPEN/TORG2040) was conducted to evaluate the efficacy and safety of first-line osimertinib for patients with EGFR mutation-positive NSCLC and poor PS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!